newsfilter
← Latest News
GlobeNewswire·

Aquestive Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Planned U.S. launch of Anaphylm™ in the first quarter of 2026, if approved by the FDA Advanced Anaphylm regulatory activities in Canada and the EUAdded clinical leadership to drive long-term successStrengthened